



Australian Government
Australian Radiation Protection
and Nuclear Safety Agency



21 March 2025

Ref: D258029

Dr Jane Canestra
Chair, Radiation Health and Safety Advisory Council
C/- council@arpansa.gov.au
619 Lower Plenty Road
Yallambie VIC 3085

Dear Dr Canestra

Re: ARPANSA response to Council advice on National registration of keratinocyte cancer

I would like to formally acknowledge the advice from the Radiation Health and Safety Advisory Council ('the Council') dated 17 April 2024 on the need for national registration of the keratinocyte cancers (basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)). ARPANSA also notes the correspondence received on 3 March 2025 regarding the background paper related to this advice being accepted for publication in the Public Health Research and Practice journal.

ARPANSA's mandate is to provide services relating to radiation protection and provide advice on radiation protection. ARPANSA provides a range services and activities that are underpinned by assessing solar UV radiation exposure and risk in the Australian population. This includes enhancing UV radiation protection of the public by providing data and promoting strategies for the prevention of health effects related to UV exposure, including keratinocyte cancers.

ARPANSA has considered the recommendations from the Council regarding the need for national registration of keratinocyte cancers, and while not directly related to our mandate, will communicate these recommendations to the relevant stakeholder (Cancer Council Australia) to further consider these important issues once the supporting journal publication is available.

I thank the Council for their time to provide me with this advice. Please note that your advice and my response will be published on the ARPANSA website.

Yours sincerely

Gillian Hirth AO
Chief Executive Officer
Australian Radiation Protection and Nuclear Safety Agency